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In order for any function to occur within a cell, transcription factors must be able 
to interact with genes. When this occurs, genes are expressed, and ultimately, proteins are 
translated and perform the specific function that needs to be done within the cell. In order 
for this to occur, genes must interact with transcription machinery. The Mediator complex 
recruits transcription factors to genes in order to promote cell-type specific gene 
expression. The Mediator complex is a multi-protein complex consisting of four modules: 
head, middle, tail, and kinase. The kinase module is known to dissociate from the rest of 
the complex in order to phosphorylate other proteins for the purposes of propagating 
signals. MED12 of the kinase module has been shown to mediate CDK8 function by 
binding to Cyclin C, allowing for phosphorylation and propagation of signals. Throughout 
this thesis, I demonstrate MED12’s role in allowing CDK8 function in promoting cell-type 
specific gene expression. Through the use of siRNA-mediated knockdowns of MED12, it 
is evident that MED12 plays a role in the initiation of adipogenesis. qRT-PCR and staining 
confirm this assumption, as there is significantly less adipogenesis occurring in hASCs 
when MED12 is knocked down. This is further evidenced by reduced expression of early 
adipogenic markers, most notably, PPAR-γ. If MED12 initiates cell type-specific gene 
expression of differentiating adipocytes, then it may be used as a target to direct fat 
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Obesity-related deaths account for about 2.8 million deaths each year. These deaths 
are an indirect result of excess fat accumulation, which leads to disorders like heart disease 
and stroke (Obesity and Overweight, 2020). Obesity is defined as a body mass index (BMI) 
greater than or equal to 30. There are three main classes of obesity. Classes I, II, and III 
include those with BMIs up to 35, 40, or higher, respectively (Overweight & Obesity, 
2021). A person with a BMI greater than 40 is considered to be extremely obese. The 
Centers for Disease Control describes body mass index as an individual’s weight divided 
by his or her height squared (kg/m²). Obesity is quickly becoming a serious problem in the 
United States, as over 40% of the total US population is currently obese, including a 
significant portion of the south (Figure 1-1). It disproportionately affects African 
Americans and Hispanics, as well as those of lower socioeconomic status (Overweight & 
Obesity, 2021). The obesity epidemic costs the US nearly $200 billion annually, with an 







1.1.2 Obesity Risk Factors 
Factors that contribute to obesity include diet, exercise, cellular response to the 
environment, and even genetics (Figure 1-2). As fast food and inexpensive processed 
meals become more widely available, the population is showing exponential weight gain. 
Therefore, researchers have recently been searching for a preventive therapy to treat 
metabolic diseases in the hopes of someday controlling the obesity epidemic that is 
currently plaguing our nation. Obesity is a growing problem across the globe, but most 
notably in the United States as the population continues to gain weight and people develop 
insulin resistance as a result (Smith & Kahn, 2016). Currently, most treatments for type II 
diabetes treat the symptoms of the disorder through the use of insulin therapies by means 
of painful injections and frequent finger pricking to monitor blood glucose levels. While 
temporarily allowing for glucose uptake and decreasing blood glucose concentrations, 
Figure 1-1: Prevalence of obesity in the United States (CDC, 2019). 
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researchers long for a permanent cure to the disease 
(Smith & Kahn, 2016).   In order to understand how to 
cure a disease like type II diabetes noninvasively, 
researchers have turned to human adipose-derived stem 
cells to control fat production and maintenance of fat 
masses in the body (Dean et al., 2020). If successful, researchers 
may be able to control fat production in order to reduce the risk 




1.2.1 Adipose Tissue 
In order for an individual to become obese, he or she must intake excess calories 
and store the unused energy as fat in the body. Fat is used as a source of energy when the 
body is fasting, but when fasting does not occur, fat continues to accumulate, leading to 
weight gain. The process of forming new fat tissue is called adipogenesis (Smith & Kahn, 
2016). 
Typically, a healthy amount of adipose tissue is necessary for normal metabolic 
function. Fat stores act as a protector of organs, as well as a ready store of free fatty acids 
when glucose is not readily available. There are three main types of adipose tissue: brown, 
beige, and white (Rosen & Spiegelman, 2014). They are classified based upon their 
apparent visual appearances, the way the fat is distributed within the cells, as well as their 




Figure 1-2: Factors 





in juvenile animals, as it allows them to maintain body temperature before larger fat stores 
are built. Beige adipose tissue is found in individuals chronically exposed to cold 
temperatures. It is more thermogenic than white adipose tissue but less thermogenic than 
brown adipose tissue. However, white adipose tissue is negatively associated with weight 
gain and metabolic issues (Rosen & Spiegelman, 2014), making it the targeted tissue of 
researchers hoping to downregulate fat formation in those suffering from obesity (Dean et 
al., 2020). Fat tissue consists of adipocytes, pre-adipocytes, immune cells, fibroblasts, and 
others, allowing it to secrete various hormones and cytokines, all of which have an effect 
on the overall functioning of the human body (Chait & den Hartigh, 2020). Fat tissue is 
capable of secreting inflammatory molecules like adipsin and TNF-α, as well as the 
hunger-depressing hormone leptin (Rosen & Spiegelman, 2014).  
 
1.2.2 Adipogenesis and Metabolism 
Increased white adipose tissue deposits result in other metabolic issues throughout 
the body. It has been shown that increased white fat storage increases inflammation in the 
body through the recruitment of cytokine-secreting macrophages. In obese humans, 
approximately 40% of adipose tissue was composed of macrophages compared to only 
10% in individuals that had a normal BMI (Weisberg et al., 2003). This upregulated 
inflammatory response has been connected to the development of type II diabetes in obese 
individuals (Chait & den Hartigh, 2020).  
Overall, the formation of adipose tissue is crucial to the development of obesity. 
Like any function within the human body, adipogenesis requires a highly regulated network 
of gene and transcription factor interaction. While several signaling pathways are involved 
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in the process including the Wnt, BMP, and CEBPβ pathways, the peroxisome proliferator-
activated receptor gamma (PPAR-γ) is considered the master regulator of adipogenesis. It 
serves as an early adipogenic marker and seems to be necessary for both initiation and 
continuation of adipogenesis (Rosen & Spiegelman, 2014). When studying stem cells, 
PPAR-γ is monitored to determine when adipogenesis starts and to what extent it is 
occurring. The only way for researchers to observe differentiation, and therefore the 
adipogenic process, is through the use of stem cells. 
 
1.3 Stem Cells and Adipogenesis  
1.3.1 Stem Cell Properties 
Stem cells have two defining properties: the ability to differentiate down a specified 
lineage or self-renew (Fuchs & Chen, 2013; Zuk et al., 2002). Stem cells can be totipotent, 
pluripotent, and multipotent. Totipotent cells are capable of differentiating into any 
embryonic cell, as well as any extraembryonic cell, including but not limited to, the 
placenta and umbilical cord. Pluripotent stem cells differentiate into any cell of the embryo, 
while multipotent stem cells are capable of differentiating into any cell of a specific cell 
lineage (Watt & Driskell, 2010). Once a cell begins the differentiation process, it cannot 
change back into a stem cell, nor can it change its future fate; it is committed (Smith & 
Kahn, 2016).  
1.3.2 Types of Stem Cells 
 There are three main types of stem cells: embryonic, induced-pluripotent (iPS), and 
adult stem cells. Embryonic stem cells are pluripotent in nature. They can differentiate into 
any cell of the embryo and are therefore extremely valuable. However, embryonic stem 
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cells can only be harvested from blastocysts, as they are not found in adults. This process 
of destroying an embryo for stem cells is highly controversial. As a result, researchers have 
turned to the more widely available adult stem cells (Yu & Thomson, 2016). 
Induced pluripotent stem cells are somatic cells that have been forced to return to 
a stem-like state. Researchers often use viral vectors to convert adult cells into pluripotent 
stem cells that are capable of differentiating down specific cell lines for regenerative 
medicine purposes. These cells are induced to differentiate by cell type-specific 
transcription factors (Ye et al., 2013). The first induced pluripotent stem cells used 
fibroblast cells and the resulting iPSCs was identical to an embryonic stem cell (Takahashi 
& Yamanaka, 2006).  
 Adult stem cells are multipotent in nature. They can differentiate into cells of 
specific cell lineages, more specifically those of the endoderm, mesoderm, or ectoderm. 
Multipotent stem cells possess the ability to self-renew and are capable of differentiating 
down specified lineages. Multipotency and self-renewal allow stem cells to replenish 
damaged tissue while also maintaining a population of stem cells (Fuchs & Chen, 2013). 
Differentiation is necessary for formation of new tissue in utero, as well as promoting the 
proliferation of new tissue during growth. Both differentiation and self-renewal are crucial 
to the development of an individual (Fuchs & Chen, 2013). Self-renewal is an important 
property of adult stem cells, but it is limited. Once self-renewal has been exhausted, and 
cells begin to senesce, aging occurs (J. Liu et al., 2020). This process is highly regulated, 
and if mutation causes more rapid self-renewal, or if injury, aging, or demand on cells is 
too much, stem cell regeneration will be depleted too quickly, leading to a multitude of 
other problems, including degeneration, atrophy, and cancer (Fuchs & Chen, 2013).  
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1.3.3 Mesenchymal Stem Cells 
Mesenchymal stem cells are a class of multipotent cells that can differentiate into 
any cell type found in the mesoderm layer of the human body, including osteocytes, 
adipocytes, myocytes, and chondrocytes (Eto et al., 2018) (Figure 1-3).  Mesenchymal 
stem cells are of increasing therapeutic interest because of their regenerative capacity and 
wide differentiation potential. Human adipose-derived stem cells, or hASCs, are a type of 
multipotent mesenchymal stem cell. They are relatively easy to harvest when compared to 
stem cells derived from bone marrow, which involves an invasive procedure with a low 
cell survival rate following transplantation. Human ASCs, on the other hand, can be 
extracted from adipose tissue through a minimally invasive liposuction procedure (Aust et 
al., 2004), and are able to be stored for future use through cryopreservation (Escobar & 
Chaparro, 2016). Since hASCs are found in adults and are easily accessible, the 
controversy regarding their use is greatly reduced when compared to the use of embryonic 
stem cells. In addition, host rejection occurs less frequently since the host and recipient are 
the same, thereby reducing the risk of graft-versus-host disease, or GVHD (Marks et al., 
2016). Therefore, it is evident that adipose-derived stem cells play a vital role in the future 




1.3.4 Clinical Use 
Currently the FDA has only approved clinical use of hematopoietic and osteogenic 
stem cells (Marks et al., 2016) due to lack of sufficient research regarding the use of other 
stem cells. In 2018 alone, there were nearly five thousand hematopoietic stem cell 
transplants in the United States to treat cancers of the blood and bone (Marks et al., 2016). 
Hematopoietic stem cells are multipotent in nature, meaning they are capable of 
differentiating into several different types of cells all within the blood cell lineage. Stem 
cells can be transplanted from an autologous or allogenic source, but autologous 
implantation has proven most successful due to GVHD (Marks et al., 2016). The success 
of hematopoietic stem cells has led researchers to begin studying other types of adult stem 
cells, including mesenchymal stem cells, which show great promise in the clinic. 
Figure 1-3: Mesenchymal stem cells are capable of differentiating into any cell of the 
mesoderm: adipocytes, myocytes, osteocytes, and chondrocytes (Eto et al., 2018). 
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Stem cell research and regenerative medicine are areas of great interest in the 
biomedical community as debilitating conditions like obesity continue to prevent patients 
from performing optimally, and ultimately lead to other serious health conditions like type 
II diabetes (Smith & Kahn, 2016). By targeting adipogenic markers in adipose-derived 
stem cells and differentiated adipocytes, fat development can be controlled (Dean et al., 
2020). If we can prevent unwanted fat from developing or downregulate its production, 
then we may be able to avoid or at least mitigate some of the complications that arise from 
obesity, including diabetes.  
 Stem cells have been used to treat some diseases in the past, and as research 
continues, their use is becoming more widespread. If successful, stem cells can be used to 
treat a larger population and possibly more diseases that affect a greater number of 
individuals. hASCs are being studied thoroughly for their potential in the treatment of 
degenerative conditions that affect tissues of the mesoderm such as muscle, cartilage, and 
even bone (Eto et al., 2018). As of 2013, there were over 300 clinical trials testing the 
application of mesenchymal stem cells (Wei et al., 2013). Mesenchymal stem cells have 
been induced to form functioning cardiac tissue (Choi et al., 2010) and been shown to yield 
positive results in treating the symptoms of MS (Stepien et al., 2016). Multiple sclerosis is 
an autoimmune, degenerative disease of the nervous system, where the central nervous 
system attacks the nervous tissue, causing severe inflammation and irreversible scarring, 
leaving the patient’s nervous system permanently damaged (What Is MS?, 2020). Due to 
the ability of adipose-derived stem cells to evade immune response, they are an ideal 
candidate for treating this disease, as the immune system is unable to attack them as 
effectively as the nervous tissue (Stepien et al., 2016).  
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 Human ASCs have also been used in cosmetic surgeries and may ultimately give 
further insight into reconstructive surgeries for patients suffering from tissue loss 
(Yoshimura et al., 2008), similar to those being discussed to treat osteoarthritis of the joints.  
1.3.5 Treatments for Metabolic Disorders 
Stem cells have been used to treat some diseases in the past, and as research 
continues, their use is becoming more widespread. However, for stem cell use to reach its 
full potential, researchers aim to find a cure to more widespread diseases, like obesity. If 
successful, stem cells can be used to treat a larger population and possibly more diseases 
that affect a greater number of individuals. 
In addition to the potential role of mesenchymal stem cells in regenerative 
therapies, they show great potential in treating metabolic diseases as well. Obesity and 
diabetes are related, as those suffering from obesity have an increased risk of developing 
insulin resistance. Fat tissue has been shown to regulate insulin sensitivity, but when fat is 
in excess, this process is severely downregulated in some patients (Smith & Kahn, 2016). 
Obesity also increases the risk for cardiovascular diseases (Carbone et al., 2019) many of 
which can result in myocardial infarction if left untreated. In the instance in which 
infarction occurs, mesenchymal stem cells have been shown to form functioning 
cardiomyocytes (Choi et al., 2010) clearly indicating another possible use as a regenerative 
therapy.  
If researchers find evidence to suggest that controlling hASC fate reduces or even 
eliminates the effects of obesity, then there will be no end to the capabilities of stem cells. 
Decreasing the number of obese individuals will reduce the harsh financial burden on the 
US, and the medical field will have a significant reduction in the number of obesity-related 
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deaths and diseases. Therefore, researchers aim to find a non-invasive, universal cure to 
metabolic disorders through the use of stem cells. The first step towards this goal is to 
determine how to control cell type-specific gene expression and stem cell fate.  
 
1.4 Regulators of Cell Fate 
1.4.1  Transcription 
 In order to maximize the potential of stem cells in the clinic, we need to have a 
better understanding for how the environment, signaling pathways, and transcription 
factors all work together to control cellular differentiation (Figure 1-4). Any external 
stimulus is capable of initiating a signaling cascade that leads to the modification of 
chromatin and the activation of genes, directing transcription and ultimately leading to the 
production of protein. The newly available proteins will perform functions throughout the 
cells to produce an effect, such as differentiation of stem cells into adipocytes. 
Transcription factors are capable of modifying chromatin by directly binding to DNA and 
are directed to the specific portion of DNA that needs modifying by a number of factors 
(Latchman, 1993). Once at specified genes, transcription factors need to be able to 
communicate with the transcriptional machinery.  In order to do this, there must be a 
modulator between cell type-specific genes and RNA Polymerase II (Allen & Taatjes, 
2015).  
12 
   
1.4.2  The Mediator Complex 
Mediator, a multi-unit protein complex, connects cell-type specific transcription 
factors to RNA Polymerase II at the promoter, thereby initiating gene expression from 
distal enhancer elements (Allen & Taatjes, 2015). Mediator is highly conserved among 
species and consists of four subunits: head, middle, tail, and kinase (Figure 1-5). The 
kinase module is made of four subunits: MED12, MED13, CDK8, and Cyclin C and can 
Figure 1-4: A variety of factors work together to control gene expression. External stimuli 
direct chromatin modifications, activate signaling pathways, and influence transcription 
factor activity. Acetylation and methylation modify chromatin by promoting the formation 
of euchromatin and heterochromatin, respectively. Transcription factors are proteins 
capable of binding to DNA at genomic enhancers and transcriptional promoters in order to 
activate transcription (Latchman, 1993) by RNA Polymerase II (Allen & Taatjes, 2015). 
This chain reaction of activating or silencing gene expression is what specifies cell fate.  
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dissociate from core Mediator through MED13 association, allowing it to function 
separately from the entire complex. Prior research shows that MED12 plays a role in the 
activation of CDK8 by binding to Cyclin C. When this interaction is interrupted, CDK8 is 
unable to phosphorylate proteins (Allen & Taatjes, 2015). When phosphorylation does not 
occur, then signal cascades cannot be propagated, preventing downstream effects like 
differentiation. Although it is clear that Mediator plays a role in regulation of transcription, 
there is much left to be uncovered. Further study of this complex and the role it plays in 
regulating cell-type specific gene expression is critical to the advancement and application 
of stem cells in the clinic. Therefore, studying MED12’s role in gene regulation will give 








Figure 1-5: The Mediator Complex is highly conserved among eukaryotic species. More 
complex organisms have paralogues to several subunits of Mediator, most notably, kinase 
module paralogues: MED12L, MED13L, and CDK19 (Allen & Taatjes, 2015). 
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1.5 Mediator and Cell Type-Specific Gene Expression 
1.5.1 The Mediator Complex Function 
 The Mediator complex has been shown to promote cell type-specific gene 
expression by acting as a bridge between genes and transcription machinery (Figure 1-6). 
MED12 specifically initiates this process by activating CDK8, a kinase known to 
phosphorylate proteins involved in the transcription cascade for gene expression (Allen & 
Taatjes, 2015). Interestingly, MED12 mutations cause severe developmental delays by 
decreasing expression of nearby genes due to the inability to bind to non-coding RNAs. 
When this occurs, Opitz-Kaveggia syndrome results, and the individual is severely 
debilitated (Lai et al., 2013). Other developmental disorders directly result from MED12 
mutations including Lujan and Ohdo syndromes, both of which are X-linked traits as 
MED12 is found on the X chromosome. These two syndromes result in the inability to 
propagate the Shh signaling cascade, resulting in the inhibition of proper nervous system 






MED12 is also mutated in most uterine leiomyomas, leading researchers to believe 
it may be a target for treating these cancers. When MED12 is mutated, Cyclin C can no 
longer bind to it, resulting in the inability of CDK8 to function. As a result, signals are not 
propagated properly, and tumors result (Turunen et al., 2014). Because of this, researchers 
are looking to target the interaction between MED12 and Cyclin C in order to prevent this 
disrupted interaction when MED12 is mutated. 
 
1.5.2 Mediator and Mammalian Development 
In addition to the work done on MED12, other subunits have already been 
implicated in cellular differentiation and adipogenesis. MED28 knockdown resulted in 
severe inhibition of peri-implantation in embryonic mice, proving MED28’s role in 
mammalian development and furthering the argument for Mediator’s role in growth and 
differentiation of tissues (Li et al., 2015). Similar to MED28, research suggests that 
MED19 plays a role in development of fat tissue. MED19, a core Mediator subunit, is 
required for the formation of white adipose tissue by bridging PPAR-γ (the master regulator 
of adipogenesis) to RNA Pol II for transcription of cell type-specific genes. When MED19 
is absent, this specific transcription cannot occur (Dean et al., 2020).  
Though MED28 and MED19 are part of core Mediator, they both play a role in 
neuronal-specific gene expression through aiding the binding of Mediator to promoter 
regions (Ding et al., 2009; Immarigeon et al., 2020; J. Yin & Wang, 2014). MED19 has 
Figure 1-6: The Mediator complex acts as a bridge between cell type-specific genes and 
transcription machinery, allowing for gene expression. 
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even been shown to allow for MED12 and MED13 interaction with core Mediator even 
when Cyclin C and CDK8 have been knocked down (Tsai et al., 2013).  
The research on MED28 and MED19 and their role in mammalian development 
suggests that other subunits in the complex may also have a critical function in regulating 
cell state. If MED12 plays a role in adipogenic gene expression during differentiation, then 
MED12 may also be an important target for directing stem cell fate to inhibit development 













2.1 Characterizing Adipogenesis and Profiling MED12 Expression 
 In order to determine the profile of MED12 expression during adipogenesis, we 
first needed to demonstrate successful differentiation of hASCs. We induced adipogenesis 
and monitored it over a fourteen-day time period to confirm lipid droplet formation. 
Following characterization of adipogenesis, we monitored MED12 transcript and protein 
expression at times that matched significant differentiation events: three, seven, and 
fourteen days. We observed that MED12 expression decreases as adipogenesis progresses, 
while PPAR-γ expression increases over time.  
 
2.1.1 Baseline MED12 Expression 
  In order to detect MED12, we used self-renewing cells to optimize conditions for 
protein expression (Figure 2-1).  
 
Figure 2-1: Baseline expression of MED12 protein using Tubulin1-α as a loading control 
(L: ladder, S: sample). 
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2.2 Characterization of Adipogenesis 
In order to understand how MED12 affects fat formation, we first characterized 
normal adipogenesis (Figure 2-2).  
 
Figure 2-2: Human adipose-derived stem cells at 10x magnification prior to adipogenic 
induction. 
 
Cells were induced to differentiate and then imaged three, seven, and fourteen days 
later (Figure 2-3). As early as seven days, lipid vesicles were observed with significantly 
more present at the end of fourteen days. 
 
 
Figure 2-3: Human adipose-derived stem cells three, seven, and fourteen days after 
inducing adipogenic differentiation. Phase contrast images taken at 4x magnification. 
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 After visually confirming that adipogenesis was occurring, RT-PCR was performed 
to determine changes in expression of MED12 and PPAR-γ, of which PPAR-γ is shown to 
increase throughout this differentiation process (Figure 2-4).  
 
Figure 2-4:  PPAR-γ expression (70bps) zero, three, seven, and fourteen days 
after inducing adipogenesis. Samples collected in triplicate.  
 
2.3 Oil Red O Optimization for Characterizing Adipogenesis  
A standard measure of adipogenesis is Oil Red O staining and quantification. In 
order to achieve high quality staining, our Oil Red O protocol required initial optimization.  
Initially, hASCs were stained seven days after inducing adipogenesis. Lipid 
droplets were unstained when viewed using the Cytation 5 BioTek plate reader, despite 




Figure 2-5: hASCs stained seven days after inducing adipogenesis. Lipid droplets were 
unstained, despite evident lipid droplet formation in the phase contrast images. 
 
After purchasing new Oil Red O stain and making the stock solution from scratch, 
lipid droplets were stained, but failing to filter the solution before staining resulted in 
significant background and clumps of Oil Red O stain precipitate. Figure 2-6 shows 
hASCs three days after inducing adipogenic differentiation where undissolved Oil Red O 
floated to the top of the PBS suspension, leaving a shadow over the stain. Although the 
stain is present, large pieces of undissolved stain sank to the bottom of the wells, making 






Figure 2-6: hASCs stained three days after inducing differentiation. Lipid droplet 
staining is evident, but Oil Red O precipitate made the images unusable. 
 
Cells were cultured again, induced to differentiate, and stained (Figure 2-7). Using 
the new stain and proper filtering, the lipid droplets were stained without any unfiltered 
precipitate. The hASCs shown below were stained fourteen days after adipogenic 
induction, and clear lipid droplet staining is evident.  
 
 
Figure 2-7: hASCs stained fourteen days after inducing adipogenic differentiation. 
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2.4 Knockdown of MED12 Results in Decreased Adipogenesis Over Time 
2.4.1 Transcript Expression  
Observing that MED12 expression decreases with PPAR-γ expression during 
adipogenesis, we then wanted to determine how decreasing MED12 expression affected 
adipogenesis and therefore PPAR-γ expression.  
Upon culturing, knocking down MED12 and inducing adipogenesis the following 
day, cells were collected at three, seven, and fourteen-day timepoints. RNA was extracted 
to validate knockdown of MED12 and expression of PPAR-γ was examined to evaluate the 
influence of this knockdown on adipogenesis.  qRT-PCR indicates transcript expression at 
the indicated timepoints, where MED12 knockdown confirmed to decrease by 97.4%, 
96.6%, and 88.0% after three, seven, and fourteen days of adipogenesis, respectively 
(Figure 2-8, Figure 2-9, and Figure 2-10). PPAR-γ expression decreased significantly 
until day fourteen.  
 
Figure 2-8: MED12 and PPAR-γ expression three days after inducing adipogenic 





Figure 2-9: MED12 and PPAR-γ expression seven days after inducing     






Figure 2-10: MED12 expression fourteen days after inducing adipogenic 




2.4.2 Oil Red O Staining 
 
Based upon relative expression of MED12 and PPAR-γ, it is evident that a decrease in 
MED12 expression results in decreased expression of adipogenic markers. Therefore, 
knockdown of MED12 inhibits adipogenesis from occurring as efficiently. In order to 
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further investigate this phenomenon, it was necessary to visualize the cells at each 





Figure 2-11: Scrambled siRNA and MED12-specific siRNA hASCs stained 
seven days after inducing adipogenic differentiation. Cells are shown in both phase 
contrast and color, at 4x and 10x magnification.  
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 Based on Oil Red O staining, it seems that decreased expression of MED12 
decreases the amount of fat formation that can occur through day seven after induction. 
However, although lipid vesicle formation is inhibited seven days into differentiation, 
we wanted to determine if the same was occurring late into adipogenesis. Therefore, 
we performed the same experiment, but waited until fourteen days after inducing 




Figure 2-12: Scrambled siRNA and MED12-specific siRNA hASCs stained 
fourteen days after inducing adipogenic differentiation. Cells are shown in both phase 
contrast and color, at 4x and 10x magnification.  
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 As suggested by the cells stained seven days after inducing differentiation, the 
same conclusions were drawn from the fourteen-day stains. Decreasing MED12 
expression before inducing adipogenesis seemed to limit the lipid formation process. 
However, the only way to be certain if there is a significant difference in the amount of 
stain present between the negative control and knockdown samples was to perform a 
stain extraction of the cells (Figure 2-13).  The stain extraction indicates that there is 
significantly less lipid present, and therefore less adipogenesis occurring, when MED12 
expression is diminished. Although PPAR-γ expression is upregulated at this timepoint, 
this may a result of diminished expression to this point, and therefore compensation for 
loss of MED12 expression.  
 There is in fact a significant difference in the amount of Oil Red O stain present 
in the MED12 knockdown cells versus the scrambled siRNA cells. These results 
indicate a significant decrease in lipid vesicle formation and Oil Red O staining when 




Figure 2-13: Oil Red O stain extraction fourteen days after inducing 
adipogenic differentiation.  
 
2.5 Delayed Knockdown of MED12 Post-Adipogenic Differentiation has 
Minimal Effect on Adipogenesis of hASCs 
As shown previously, MED12 seems to play a role in initiating the transcription 
of cell type-specific genes, as expression typically decreases over time as adipogenesis 
progresses. In order to provide further evidence for MED12’s role in early 
differentiation or to determine where specifically in differentiation MED12 has a role, 
we performed a delayed knockdown study, reducing the expression of MED12 three 
and seven days after inducing adipogenesis (Figure 2-14).  
The first groups of cells were transfected with MED12-specific siRNA prior to 
adipogenic differentiation, the second group was transfected with siRNA three days 
into the adipogenic process, and the final group was transfected with siRNA seven days 
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into adipogenesis. All RNA and protein samples were collected fourteen days after 
induction of differentiation.  
 
Figure 2-14: Experimental setup of delayed knockdown experiments.  
 
MED12 knockdown was validated using endpoint PCR, qRT-PCR, and western 
blots, all of which indicated knockdown of MED12 for all three timepoints. 
   
2.5.1 MED12 and PPAR-γ Transcript Expression 
 Given our uncertainty about efficiency of knockdown during adipogenesis, we 
first performed RT-PCR to see if we could observe decreased MED12 transcript at each 
time point (Figure 2-15). Indeed, we saw that when MED12 siRNA is present, MED12 
transcript is expressed at significantly lower levels when compared to the negative 
control samples.  
 PPAR-γ expression is not significantly higher or lower in the MED12 
knockdown samples for all three timepoints as well, indicating that adipogenesis is 
minimally affected by a decrease in MED12 expression. This may suggest that MED12 
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is not required later in adipogenesis, but only in the earlier stages of cell fate 
commitment.  
 The apparent increase in PPAR-γ expression when MED12 is knocked down 
seven days after inducing adipogenesis may suggest a compensatory role of the 
adipogenic marker to maintain adipogenesis when MED12 is depleted.   
 
 
Figure 2-15: MED12 (87 bps) expression after knocking down (KD) one day 
prior to the differentiation process (PD), and three (3d) and seven (7d) days after 
inducing adipogenesis, using GAPDH (99 bps) as a loading control.   
 
 Following confirmation of knockdown, we wanted to quantify any changes in 
MED12 expression. Gene expression of MED12 and PPAR-γ was determined using 




Figure 2-16: Pre-differentiation Knockdown qRT-PCR. Data was normalized 
to GAPDH and samples were analyzed in triplicate. 
 
 
Figure 2-17: Day 3 Delayed Knockdown qRT-PCR. Data was normalized to 




Figure 2-18: Day 7 Delayed Knockdown qRT-PCR. Data was normalized to 
GAPDH and samples were analyzed in triplicate.  
 
   
2.5.2 MED12 and PPAR-γ Protein Expression 
 We further validated our observations by evaluating protein expression, as this 
does not always match transcript expression. MED12 protein expression is significantly 
lower in the MED12 knockdown samples versus the negative control samples when 
knockdown was performed one day prior to inducing adipogenesis (PD), as well as 
three (3d) and seven (7d) days after inducing adipogenesis. Using the same timepoints 
as before, protein expression of MED12 and PPAR-γ during MED12 knockdown 
compared to normal MED12 expression was determined during adipogenesis, using 
GAPDH as a loading control (Figure 2-19). PPAR-γ is shown as two separate bands in 
the western blot: one band at 53 kDa and another at 57 kDa. This is due to the non-
specificity of the PPAR-γ antibody resulting in detection of both PPAR-γ1 and PPAR-
γ2 (M. C. Liu et al., 2020). MED12 evidently affects expression of other proteins as 
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well, evidenced by decreased expression of GAPDH. However, Image J analysis needs 
to be performed to confirm if this change is in fact significant.  
 
Figure 2-19: MED12 and PPAR-γ protein expression when MED12 
expression is decreased one day prior to inducing adipogenesis (PD), and three (3d) 
and seven (7d) days after inducing adipogenic differentiation. All cells were collected 
fourteen days after inducing adipogenic differentiation (L: ladder, NC: negative 
control, KD: knockdown). 
 
 After confirming efficient knockdown, we sought to evaluate adipogenesis in 
each of these knockdown assays. PPAR-γ expression significantly decreased from the 
negative control to the knockdown samples when knockdown of MED12 was 
performed both one day prior to inducing adipogenesis, as well as three days after 
inducing adipogenesis. However, PPAR-γ expression was comparable between 
negative control and knockdown samples when knockdown was performed seven days 
after inducing adipogenesis. This suggests that MED12 may play a role in early 
adipogenesis, but its absence late in adipogenesis has little effect on continuing fat 
formation. However, PPAR-γ transcript and protein expression conflict. Transcript 
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shows increased expression in the MED12 knockdown cells for all delayed 
knockdowns, but protein expression shows significant downregulation when MED12 
is knocked down during adipogenesis. 
 
 
2.5.3 Delayed Knockdown Oil Red O Staining 
 Following observations of changes in gene and protein expression, we wanted 
to visualize the change in adipogenesis through the use of Oil Red O staining.  
 Using the same timepoints as before, lipid droplets in hASCs were stained with 
Oil Red O after 14 days of adipogenesis with MED12 siRNA transfections having taken 
place one day prior to inducing adipogenesis, three days after inducing adipogenesis, 
and seven days after inducing adipogenesis (Figure 2-20).  
 
 
Figure 2-20: Oil Red O staining of hASCs when MED12 is knocked down one day 
prior to inducing adipogenesis and three and seven days after inducing adipogenesis. 
 
36 
 A stain extraction was performed to quantify the differences in stain present 
between the negative control and knockdown samples (Figure 2-21). The Oil Red O 
stain extraction indicates more lipid droplet formation in the negative control 
knockdown versus the MED12 knockdown samples when knockdown was performed 
one day prior to adipogenic induction (PD), as well as three days after adipogenic 
induction (Day 3). However, lipid droplet formation was comparable between the 
negative control and MED12 knockdown samples when knockdown was performed 
seven days after inducing adipogenesis. Consistent with the protein expression studies, 
this gives indication that MED12 is required for initiating adipogenesis but may not 
play a role in late adipogenesis.  
 
 
Figure 2-21: Delayed MED12 knockdown experiments Oil Red O stain extraction 
when MED12 is knocked down one day prior to inducing adipogenesis (PD) and three 




MED12 plays a crucial role in transcription of cell type-specific genes. Previous 
research suggests that MED12 mutation results in uterine leiomyomas, X-linked 
developmental disorders, and even disruption of the Shh signaling cascade. All of these 
disorders directly result in interruption of normal developmental processes. Given the 
importance of adipogenesis in development and the role it plays in disease, we sought 
to determine how decreasing expression of MED12 affects adipogenesis of hASCs. 
When MED12 is present, hASCs differentiate to their full potential, and when MED12 
expression is decreased before inducing adipogenesis, differentiation is diminished. 
When profiled over time, MED12 expression was observed to decrease following the 
induction of adipogenesis, indicating a more crucial role in early adipogenesis. This is 
confirmed by prior research in the lab (Allen and Taatjes, 2015), as MED12 has been 
shown to initiate transcription, while adipogenic markers like PPAR-γ remain present 
and active throughout differentiation.  
When MED12 is knocked down later in adipogenesis, it seems to play less of a 
role, as PPAR-γ transcript is not significantly affected by decreasing MED12 
expression seven days after the induction of adipogenesis, and in some cases, it even 
increases in expression, possibly to compensate for loss of MED12 function. However, 
protein expression of PPAR-γ did not follow the same trend. PPAR-γ showed 
significant downregulation when MED12 expression was decreased one day prior to 
inducing adipogenesis, as well as three days after inducing adipogenesis, but not seven 
days post-induction. This observation was confirmed through Oil Red O stain 
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extraction, suggesting that adipogenesis is significantly inhibited when MED12 is 
knocked down before adipogenesis, as well as three days after beginning the process, 
but not seven days after inducing.  
Overall, it is evident that MED12 plays a role in early differentiation of hASCs. 
MED12’s responsibility in activating CDK8 through Cyclin C binding is crucial to cell 
type-specific gene expression. Interruption of this interaction downregulates 
transcription, providing evidence that complete knockout of MED12 likely prevents 
cell type-specific transcription from occurring at all.  
If this is true, then MED12 is a potential target for stem cell therapies, like those 
currently being researched for ending the obesity epidemic. If so, then fat cell formation 
can be controlled in order to direct it to become browner in nature, thereby promoting 
thermogenesis, or prevent white fat from forming, resulting in decreased effects from 
fat accumulation. If this is possible, then we can prevent obesity-related diseases from 
plaguing our world, and the obesity epidemic will be cured by a non-invasive, 





















3.1 Cell Culture 
3.1.1 Complete Culture Media (CCM) 
 Prior to making media, MEM Alpha (1X) (ThermoFisher Scientific 12561049), 
fetal bovine serum (FBS) (Atlanta Biologicals S11550), 200mM L-Glutamine (L-Glut) 
(Gibco 25030-081), and pen strep were warmed to 37°C. Using a 250 mL Corning filter 
system (VWR 28199-770) under a sterile hood, 203.75 mL MEM Alpha (1X), 41.25 mL 
FBS, 2.5 mL L-Glut, and 2.5 mL pen strep were mixed and filtered. Media was stored at 
4°C for up to two weeks. 
3.1.2 Thawing Adipose Stem Cells 
 Cells were thawed in a 37°C water bath before being transferred to pre-warmed 
CCM. Cells were centrifuged at 1,500 RPM and then resuspended in CCM. The cells were 
plated onto a 10 cm tissue culture-treated plate. The following day, media was changed. 
Media was then changed every 48 hours until the cells reached 70–80% confluency. 
3.1.3 Passaging Adipose Stem Cells 
 Cells were passaged when they reached 70-80% confluency. A 0.25% Trypsin-
EDTA (Life Technologies 25200-056) was added to the cells and then incubated at 37°C 
for 3 minutes for detachment. CCM was added to neutralize the trypsin reaction. The 
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contents of the plate were then centrifuged for 1,500 RPM. When centrifugation was 
complete the cells were resuspended in CCM. 0.4% Trypan Blue was used to stain the cells 
Using a Countess II FL Hemacytometer and a Countess II FL machine, a cell count was 
determined. Using the live cell count, cells were plated according to Table 3-1. Media was 
changed 24 hours later, and then every 48 hours until cells reached 70–80% confluency.  
  
Plate Number of Cells per 
Plate/Well 
Total Volume of CCM 
10-cm 100,000 10 µL 
6-cm 45,000 3 µL 
6-well 20,000 2 µL 
 
3.1.4 Transfection 
 hASCs were transfected when they reached 30-50% confluence with either 
negative control or MED12-specific siRNA. Negative control siRNA (5nmol/mL) 
(ThermoFisher Scientific 4390843) was combined with an equal amount of 2% 
Lipofectamine RNAiMAX reagent (Life Technologies 13778075) in 1X OptiMEM I 
solution. This was also completed using a MED12-specific siRNA (5nmol/mL) 
(ThermoFisher Scientific s19364). The solutions were added to the cells and incubated for 
24 hours before media was replaced with differentiation media. 
 
Table 3-1: Number of cells seeded based upon size of plate/well. 
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3.1.5 Adipogenesis 
 Adipogenesis was induced in cells once they reached 80% confluency through the 
addition of AdipoQual (LaCell LLC LaADM-500) medium. Media was changed every 72 
hours until differentiation was complete.  
 
3.2 Characterization 
3.2.1 Oil Red O Staining 
 An Oil Red O stock solution was prepared using 0.5g of solid Oil Red O (VWR 
11411-412) and 100mL of 100% isopropanol. An Oil Red O working solution was then 
prepared using 3 parts of Oil Red O stock solution per 2 parts of distilled water. The 
solution was then filtered through a syringe filter (CELLTREAT 229747) A 10% formalin 
solution was then added to the cells and incubated at room temperature for 15 minutes. The 
Oil Red O working solution was added, and the cells were incubated for 20 minutes at 
room temperature. The cells were viewed using a Cytation 5 BioTek Plate Reader.   
 
3.3 Protein Expression 
3.3.1 Protein Extraction 
 After rinsing with PBS (ThermoFisher Scientific 10010023), cold 1X RIPA lysis 
buffer containing protease and phosphatase inhibitor was added to the cells. The cells were 
then scraped and rotated for 30 minutes at 4°C, and then centrifuged at 4°C at 12,000 RPM 
for 20 minutes. The supernatant was removed and stored at -80°C, while the pellet was 
discarded.  
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3.3.2 Bradford Protein Assay 
 A 20% Bradford buffer was made using protein dye and distilled water. Six 
standards were mixed using BSA, water, and buffer. Proteins of unknown concentrations 
were mixed with buffer and distilled water and were pipetted into a clear bottom 96-well 
plate in duplicate. The plate was read using a Cytation 5 BioTek plate reader to determine 
the absorbance value of each sample.  
 
3.3.3 Western Blot 
 Before beginning, a 10% running buffer was made, as well as a 10% Tris/Glycine 
buffer, which is stored in the fridge until use.  Laemmli buffer (Biorad 1610737), water, 
and protein solution was made using the protein concentrations determined from the 
Bradford protein assay. The samples were heated at 100°C and then spun down. The 
protein samples were loaded into the gel (Biorad 456-1084) and run at 120V for 90 minutes 
with a standard for comparison (Bio-Rad, Catalog #1610376).  
 In order to transfer the protein to the membrane, the following items were 
“sandwiched” on top of each other, making sure to pop any bubbles in the process: sponge, 
filter paper, PVDF membrane (Biorad 1704156), gel, filter paper, sponge. The gel and 
membranes must remain wet with transfer buffer throughout this process. The gel was 
transferred at 100V for 60 minutes. 
 The membrane was then rocked in a non-fat milk (Cell Signaling Technology 
99995) blocking buffer for 60 minutes. Using this buffer, primary antibody solutions were 
made. After cutting the membrane according to protein size, the membrane pieces were 
probed overnight in the fridge.  
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 The following day, the membranes were washed 5 times with TBST (1X) and then 
probed using a secondary antibody solution for 60 minutes. After rinsing 5 more times, 
Western ECL reagents were mixed 1:1 and then pipetted onto the surface of the membranes 
in the dark due to light sensitivity. Pictures were then taken of the membranes.  
 
3.4 Gene Expression 
3.4.1 RNA Collection and Extraction  
 RNA was collected using Trizol reagent (Thermo Scientific 15596018) following 
the manufacturer’s protocol. The cells were then collected and stored at -80°C until 
extraction. 
 Collected RNA was retrieved from -80°C freezer and allowed to thaw at room 
temperature. Chloroform was added to each sample. The samples were agitated, incubated 
at room temperature, and then centrifuged at 4°C at 12,000 xG. The clear supernatant was 
removed, and the phenol waste was discarded. Glycogen (5mg/mL) (ThermoFisher 
Scientific R0551) was added to each sample, followed by 100% isopropanol. The samples 
were incubated at room temperature and then centrifuged at 4°C at 12,000 xG. The liquid 
supernatant was removed, leaving the RNA pellet behind. 75% ethanol was used to wash 
the RNA pellet, then the samples were centrifuged again at 4°C at 7,500 xG. The liquid 
supernatant was removed and the RNA pellet remained. The pellet was resuspended in 
nuclease-free water (VWR 10220-404) and stored at -80°C.  
 RNA was quantified using a spectroscopy program on a Cytation 5 BioTek Plate 
Reader.  
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3.4.2 cDNA Synthesis 
 cDNA was synthesized using 1 µg of RNA, nuclease-free water, and qScriptTM 




 Using GoTaq Green Master Mix (Promega M7122), cDNA, nuclease-free water, 
and primers (Table 3-2), PCR was run in a thermal cycler for 30 cycles at 60°C. The 
samples were run through an agarose (VWR 97062-250) gel via electrophoresis.  
3.5.2 qRT-PCR 
 qRT-PCR was performed in technical triplicate using PowerUp SYBR Green 
Master Mix (Applied Biosystems A25742), nuclease-free water, forward and reverse 
primers (Table 3-2), and 1 µL cDNA per reaction in a 96-well plate. The reaction was 
run using a StepOnePlusTM Applied Biosystems machine standard quantitation 











Gene Forward Sequence Reverse Sequence Product Size 
(bp) 
GAPDH ACTAGGCGCTCACTGTTCTCT CAATACGACCAAATCCGTTGACT 99 
Tubulin1-α CCAGGGCTTCTTGGTTTTCC CGCTCAATGTCGAGGTTTCT 267 
MED12 CGAAAAGGGACAGCAGAAAC CCCATCCTCCCCACCTAAGA 87 
PPAR-γ GTGGTACTTTACGCCTCGGT GCTCGGTTACTCCCCGTTTC 70 
 
 







CONCLUSIONS AND FUTURE WORK 
 
4.1 Conclusions 
Here we sought to investigate the role MED12 plays in cell type-specific gene 
expression by studying its role in adipogenesis of human adipose-derived stem cells. Based 
on the data shown, MED12 plays a role in the initiation of adipogenesis. However, MED12 
does not play as great a role in continuing differentiation. When MED12 expression is 
decreased prior to inducing differentiation, adipogenesis is diminished. When we looked 
further to determine a more precise role for MED12, we found that delaying the knockdown 
and transfecting cells that are already undergoing differentiation resulted in no significant 
difference in differentiation potential of the adipose stem cells compared to when MED12 
expression was unchanged. Knowing that MED12 initiates cell type-specific gene 
expression by binding to Cyclin C and activating the kinase function of CDK8 (Allen & 
Taatjes, 2015), then decreasing MED12 expression must inhibit this process by preventing 
phosphorylation and downstream events, like differentiation. The results presented in this 
thesis suggest that MED12 is crucial to transcription of adipose-specific genes, and when 
MED12 expression is diminished, hASCs are unable to differentiate as effectively. The 
results presented here support previously published literature as well. Since MED12 is 
essential to the activation of CDK8 kinase function, if MED12 was completely absent, it 
48 
is likely that no differentiation would occur at all, compared to the minimal lipid formation 
seen when MED12 expression is only decreased. MED12 is key to several developmental 
pathways, including, but not limited to, Wnt, β-catenin, and Shh. Interruption of any of 
these vital pathways results in severe developmental disability (Straub et al., 2020). It is 
evident that MED12 is crucial for growth, and without it, development of the neural crest 
(Rau et al., 2006) and, based upon this research, differentiation of hASCs into adipocytes, 
would likely be impossible. Tumors would result, as mutated MED12 expression 
oftentimes results in uterine (Mäkinen et al., 2017) and breast tumors (Nagasawa et al., 
2015). If MED12 was completely knocked out, lethality would likely be inevitable (J. W. 
Yin & Wang, 2014). Therefore, MED12 is essential to cell type-specific gene expression 
and proper mammalian development.  
The Mediator complex is essential for the proper regulation of cell type-specific 
gene expression (Allen & Taatjes, 2015). MED12 in particular is known to act as an 
initiator of cell type-specific gene expression by activating the kinase function of CDK8, 
without which, propagation of signal cascades would be impossible. Without proper 
signaling pathways, gene activation and further differentiation will not occur (Clark et al., 
2015). As we develop an understanding of the role that specific subunits of the complex 
play in cell fate determination, we will better be able to control stem cells and ultimately, 
provide relief for disorders that are currently deemed incurable.  
Adipose-specific genes are activated by direct binding of transcription factors to 
DNA. RNA Polymerase II then transcribes these adipose-specific genes, resulting in fat 
formation, and ultimately, adipogenesis. However, RNA Polymerase II must be recruited 
to the activated genes in order to perform transcription. The Mediator complex is capable 
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of modulating the interaction between RNA Polymerase II and cell type-specific genes in 
order for adipogenesis to occur (Allen & Taatjes, 2015). 
However, as shown previously, the entire Mediator complex plays an important 
role in development, with each subunit performing a different function in growth and tissue 
repair. MED28 plays a role in peri-implantation as knockout proves fatal in mice (Li et al., 
2015). MED19 controls white adipose tissue development by bridging PPAR-γ and RNA 
Polymerase II together for transcription (Dean et al., 2020). And finally, through the data 
shown in this paper, MED12 plays an important role in differentiation of hASCs into 
adipocytes, providing further evidence to the Mediator complex’s important role in 
development.  
MED12 is implicated in a number of developmental defects and human disease, 
including breast cancers (Nagasawa et al., 2015), uterine fibroids (Turunen et al., 2014), 
and even X-linked disorders like Lujan and Opitz–Kaveggia syndromes (Srivastava et al., 
2019). Typically when MED12 is mutated, signals are no longer propagated as effectively, 
meaning mutation result and tumors form (Turunen et al., 2014). As people have 
recognized the role of MED12 in these conditions, they have recognized MED12 mutation 
as the common element. However, no cure for MED12 mutation has yet to be uncovered. 
Previous research directing stem cell fate of mesenchymal stem cells into cardiomyocytes 
(Choi et al., 2010) and chondrocytes (Stepien et al., 2016) shows the promise behind these 
stem cells. If these cells can be induced to form other cells of the mesoderm, then through 
gene therapy, adipose tissue, which arises from mesenchymal stem cells, should be able to 
be directed to form brown adipose tissue from white adipose tissue through transcription 
factor manipulation (Dean et al., 2020). This would effectively reduce the effects of obesity 
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on those suffering. If we can determine a way to control MED12 functioning to promote 
formation of brown fat and inhibit formation of white fat without resulting in tumor 
formation, then it will become possible to control fat formation and prevent obesity-related 
illness using gene therapy.  
 
4.2 Future Work 
The Mediator complex is highly conserved (Allen & Taatjes, 2015), giving clear 
indication to its importance for development and growth of all organisms. Although 
MED12 has been shown to initiate cell type-specific gene expression, decreasing its 
expression over time does have an effect on adipogenesis, evident by decreased expression 
of adipogenic markers when MED12 is knocked down. However, more research needs to 
be performed to determine how MED12 knockdown late in adipogenesis affects the 
process. It is possible that adipogenic markers compensate for loss of MED12, thereby 
continuing the differentiation process even when MED12 is not present. It may be 
necessary to perform a double knockdown, by simultaneously knocking down MED12 and 
PPAR-γ late in adipogenesis. If adipogenesis is significantly affected, then it is likely that 
PPAR-γ compensates for MED12 loss through upregulation. MED12’s effect on 
expression of other important proteins, including PPAR-γ, Cyclin C, and CDK8, must be 
determined as well. GAPDH expression appears to decrease after diminishing MED12 
transcript expression, but Image J analysis needs to be performed to confirm this 
phenomenon.  
But what actually controls MED12 function remains to be uncovered as well, and 
if cell signals released by cells undergoing MED12-initiated differentiation could be 
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signals to undifferentiated cells to begin the process. There may be a cascade of events that 
result from one cell beginning initiation of cell type-specific gene expression that is simply 
continued once these signals are released. By collecting adipogenic media aspirated from 
cells after varying timepoints, this conditioned media could be used to induce 
differentiation in self-renewing hASCs. While adipose-specific transcription factors are 
likely exhausted, the differentiated cells may have released other signals during 
adipogenesis that may aid self-renewing cells in differentiation as well. Varying adipogenic 
markers, like PPAR-γ, LPL, or even CEBP-α, can be used to confirm that adipogenesis is 
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